This family of epigenetic drugs is intensively assessed in ongoing cancer clinical trials and those liver tumors harboring NSUN7 epigenetic inactivation might constitute an unexpected niche of patients where these compounds could possess efficacy. This evidence concerns the gene NSUN7 and cancer.